Login to Your Account

Financings NEWS

While Agios Pharmaceuticals Inc. waits to hear from the FDA about its AML therapy's NDA, the company is mulling the prospect of an eventual label "in newly diagnosed patients unfit for any therapy," CEO David Schenkein said.

With more than two decades of experience in immunology and inflammatory diseases, Anthony Coyle was hankering for the opportunity to shift the treatment paradigm from systemic immunosuppressives  to "a different type of approach" that would modulate the immune system.

LONDON – Pherecydes Pharma SA has raised $10.3 million in a series B round, which it said will enable it to get approval for its bacteriophage manufacturing system and to make products available for treating serious antibiotic-resistant infections on a compassionate use basis.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: